Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by subaru1ion Mar 31, 2024 7:49pm
117 Views
Post# 35961999

mdjbrown....read between the lines...'launching generic

mdjbrown....read between the lines...'launching generic Epidiolex in the U.S.'   That means the submission is already at the FDA level and awaiting approval.  

AND.............

LABS mentioned clearly, launching generic Epidiolex in the U.S. and by using SEDDS technology (remember, Trunerox is CBD also) from Avicanna, it distinguishes itself in DELIVERY form as well.   A more effective generic than the original!!!

IF the LABS generic form of Epidiolex were to only capture 20% of that market, that's a nifty $200 million in revenues for LABS.   

I can't argue with Pidduck, LABS is undervaled ;-)

<< Previous
Bullboard Posts
Next >>